Pint Pharma to market PharmaMar's marine-derived anticancer drug, Aplidin in Latin American countries
PharmaMar has announced the signing of a commercialization and distribution license agreement with Pint Pharma International, S.A. for the marine-derived anticancer drug Aplidin (plitidepsin) in Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, Mexico, Paraguay, Peru, Uruguay and Venezuela.
According to the agreement, Pint will pay undisclosed milestone and royalty payments to PharmaMar in exchange for the rights to register, commercialize and distribute Aplidin in each of the foresaid territories. PharmaMar will retain exclusive production rights and will supply the finished product for clinical and commercial use.
The company announced at the ASH Congress during December 2017, in San Diego (USA), the results in a pivotal phase III clinical trial (ADMYRE) with plitidepsin, where the primary endpoint, progression free survival, and secondary objectives, overall survival and safety were met; providing the treatment for multiple myeloma with a novel mechanism of action.
According to Luis Mora, managing director of Pharma Mar's Oncology Business Unit, "We are about to address our first strategic alliance with Pint Pharma International for the commercialization of Aplidin, developed to tackle multiple myeloma. This agreement is aligned with our commitment to bring novel and first-in-class therapies to patients worldwide."
David Muñoz, CEO of Pint Pharma, stated that, "We are excited with the opportunity of including Aplidin into our comprehensive hematology oncology portfolio; this will further strengthen our mission to enable the Latin American population with severe life-altering conditions to live better lives by providing early and efficient access to innovative therapeutic solutions."
Pint Pharma is a private, Latin American focused pharmaceutical company, devoted to the development, registration and commercialization of specialty based treatments. Pint Pharma benefits from leaders with extensive experience in the pharmaceutical sector and who are based strategically throughout Latin America and Europe.
Headquartered in Madrid, PharmaMar is a world-leading biopharmaceutical company in the discovery and development of innovative marine-derived anticancer drugs. The company has a pipeline of drug candidates and a robust R&D oncology programme.